Dihexa

Overview

Dihexa (N-hexanoyl-Tyr-Ile-(6)-aminohexanoic acid amide) is a synthetic oligopeptide analog derived from angiotensin IV, developed at Washington State University as a blood-brain-barrier-penetrant investigational compound for neurotrophic and synaptogenesis research. In the laboratory it has been studied as a potent inducer of new synaptic connections, reported to act through the hepatocyte growth factor (HGF)/c-Met signaling pathway. It is used strictly as a research reference material. Vialdyne releases Dihexa as a lyophilized peptide against a ≥99.0% HPLC main-peak specification, supplied with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, appearance, and water content. Lots are released only after the COA is on file.

Applications & buyer fit

Cognitive and neuropeptide buyers are predominantly research labs running in vivo rodent studies. The dominant administration route in the literature is intranasal, these peptides are not meaningfully blood-brain-barrier permeable when delivered systemically. For in vivo workflows, endotoxin and microbial-limit testing is recommended at the COA stage so the bioassay readout is not confounded by contamination unrelated to the test article.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

1401708-83-5

Molecular Formula

C27H44N4O5

Molecular Weight

504.7 Da

Sequence

Hexanoyl-Tyr-Ile-Ahx-NH2

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 12.68 days

MOQ

On request

Lead time

10–18 days

Storage

Room temperature, protect from light

Certificate of Analysis

Representative COA previews for Dihexa; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Dihexa

VD260428-DIH062 · 99.27%

VerifiedRequest full COA →

Dihexa

VD260428-DIH061 · 98.93%

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

1. Sun X, Deng Y, Fu X, Wang S, Duan R, Zhang Y. AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. Brain Sci. 2021;11(11):1487.
2. McCoy AT, Benoist CC, Wright JW, Kawas LH, Bule-Ghogare JM, Zhu M, Appleyard SM, Wayman GA, Harding JW. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154.
3. Hua X, Church K, Walker W, L'Hostis P, Viardot G, Danjou P, Hendrix S, Moebius HJ. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial. J Alzheimers Dis. 2022;86(3):1399-1413.
4. Devanand D, et al. (Athira Pharma). Fosgonimeton (ATH-1017) Phase 2/3 LIFT-AD Trial in Mild-to-Moderate Alzheimer's Disease [trial results reported 2024]. Registered as ClinicalTrials.gov NCT04488419.

Frequently asked questions